Pasar al contenido principal

DETECCION, EN SEGUNDO TRIMESTRE, DE LOS FALSOS POSITIVOS DEL CRIBADO DE PREECLAMPSIA DE PRIMER TRIMESTRE (STOPPRE)

PI17/01944

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización HOSPITAL VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia, Post hoc analysis of trial

  • Ricart, Marta|||0000-0003-0099-6525
  • Bonacina, Erika|||0000-0002-8042-8247
  • García Manau, Pablo|||0000-0002-2415-1626
  • López, Monica
  • Caamiña Álvarez, Sara|||0000-0001-9178-3132
  • Vives, Àngels|||0000-0001-9712-6379
  • Lopez-Quesada, Eva|||0000-0002-4477-3246
  • Maroto, Anna|||0000-0003-3225-9095
  • de Mingo, Laura
  • Pintado, Elena
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Martin, Lourdes|||0000-0003-1781-5305
  • Rodriguez-Zurita, Alicia|||0000-0003-4177-4726
  • Garcia Cancela, Esperanza|||0000-0001-8924-9096
  • Pallarols Badia, Mar
  • Pratcorona Alicart, Laia|||0000-0002-3805-1589
  • Teixidor, Mireia|||0000-0001-8548-1648
  • Orizales Lago, Carmen María|||0000-0001-7184-2799
  • Ocaña, Vanesa|||0000-0003-2547-5646
  • del Barco, Ester|||0000-0002-1484-9027
  • Carreras Moratonas, Elena|||0000-0003-3471-7248
  • Suy, Anna|||0000-0003-2987-6105
  • Mendoza, Manel|||0000-0002-3030-3833
This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women at high risk after first-trimester combined screening for preeclampsia (PE) and normal placental growth factor (PlGF) levels at 24-28 weeks of gestation. This is a post hoc analysis of the StopPRE trial, conducted at nine Spanish maternity hospitals from September 2019 to September 2021. In the StopPRE trial, all high-risk single pregnancies identified during first-trimester screening for PE were treated with 150 mg of daily aspirin. Out of 1604 eligible women with a soluble fms-like tyrosine kinase-1 to PlGF ratio (sFlt-1/PlGF) ≤38 at 24-28 weeks, 968 were randomly assigned in a 1:1 ratio to either continue aspirin until 36 weeks (control group) or discontinue it (intervention group). In this secondary analysis, only women with PlGF ≥100 pg/mL at 24-28 weeks were included. As in the StopPRE trial, the non-inferiority margin was set at a 1.9% difference in preterm PE incidence between the groups. Among the 13 983 screened pregnant women, 1984 (14.2%) were deemed high-risk for preterm PE, of which 397 (20.0%) were ineligible, 636 declined participation, and 32 were excluded. Ultimately, 919 women with PlGF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories, Post Hoc Analysis of a Randomised Trial

  • Bonacina, Erika|||0000-0002-8042-8247
  • Armengol-Alsina, Mireia|||0000-0002-2087-5176
  • García Manau, Pablo|||0000-0002-2415-1626
  • Lopez Rodriguez, Monica|||0000-0002-3125-9870
  • Rodriguez-Zurita, Alicia|||0000-0003-4177-4726
  • Vives, Àngels|||0000-0001-9712-6379
  • Lopez-Quesada, Eva|||0000-0002-4477-3246
  • Ricart, Marta|||0000-0003-0099-6525
  • Maroto, Anna|||0000-0003-3225-9095
  • de Mingo, Laura
  • Pintado, Elena
  • Arias-Garcia, Andrea
  • Martin, Lourdes|||0000-0003-1781-5305
  • Chulilla Perez, Carolina|||0000-0002-3860-5377
  • Garcia Cancela, Esperanza|||0000-0001-8924-9096
  • Pallarols, Mar
  • Vidal-Sagnier, Laia
  • Teixidor, Mireia|||0000-0001-8548-1648
  • Orizales Lago, Carmen María|||0000-0001-7184-2799
  • Pérez-Gomez, Adela
  • Ocaña, Vanesa|||0000-0003-2547-5646
  • Puerto Tamayo, Linda Grace|||0000-0001-5539-6397
  • Millán, Pilar
  • Diaz, Sonia
  • del Barco, Ester|||0000-0002-1484-9027
  • Dalmau, Marta
  • Rolle, Valeria|||0000-0002-1793-7049
  • Carreras Moratonas, Elena|||0000-0003-3471-7248
  • Suy, Anna|||0000-0003-2987-6105
  • Mendoza, Manel|||0000-0002-3030-3833
Objective: To compare the trajectories of placental biomarkers throughout pregnancy after aspirin discontinuation at 24-28 weeks with those of a cohort treated until 36 weeks of gestation. Design: A longitudinal secondary analysis of the StopPRE trial, using repeated measures of soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and their ratio. Setting: Nine maternity hospitals across Spain. Population: The original StopPRE trial included 936 women at high risk for preterm preeclampsia based on first-trimester screening. All participants received aspirin 150 mg daily until randomisation at 24-28 weeks. At that point, 463 women were assigned to continue aspirin until 36 weeks, while 473 were assigned to discontinue it. Methods: sFlt-1, PlGF, sFlt-1/PlGF were measured at baseline (24-28 weeks) and during follow-up visits at 28-32, 32-36, and after 36 weeks of gestation. Linear mixed-effects models (LMM) with treatment-by-gestational age interaction were used to analyze biomarker trajectories over time. Main Outcome Measures: Differences in trajectories of raw values and multiples of the median for sFlt-1, PlGF, sFlt-1/PlGF between groups. Results: Among 463 participants in the aspirin continuation group and 473 in the discontinuation group, 3483 measurements of each biomarker were analysed. There were no significant differences in the trajectories of sFlt-1, PlGF, or sFlt-1/PlGF between groups (p-values for raw analysis: 0.662, 0.728 and 0.979, respectively). Conclusions: In women at high risk of preterm preeclampsia, discontinuing aspirin at 24-28 weeks did not alter the trajectories of placental biomarkers. This may explain why stopping aspirin did not increase preterm PE risk in the StopPRE trial.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial

  • López, Monica
  • Vives, Angels
  • Lopez-Quesada, Eva
  • Castillo-Ribelles, Laura
  • Carreras Moratonas, Elena
  • Bonacina, Erika
  • Garcia-Manau, Pablo
  • Caamiña Álvarez, Sara
  • Maiz, Nerea
  • Suy Franch, Anna
  • Mendoza, Manel
Doppler; Aspirin; Pre-eclampsia, Doppler; Aspirina; Preeclampsia, Doppler; Aspirina; Preeclampsia, Objective To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24–28 weeks. Design Post-hoc analysis of a clinical trial. Setting Nine maternity hospitals in Spain. Population or Sample Pregnant individuals at high risk of pre-eclampsia at 11–13 weeks and normal uterine artery Doppler at 24–28 weeks. Methods All participants received treatment with daily aspirin at a dose of 150 mg. Participants were randomly assigned, in a 1:1 ratio, either to continue aspirin treatment until 36 weeks (control group) or to discontinue aspirin treatment (intervention group), between September 2019 and September 2021. In this secondary analysis, women with a UtAPI >90th percentile at 24–28 weeks were excluded. The non-inferiority margin was set at a difference of 1.9% for the incidence of preterm pre-eclampsia. Main outcome measures Incidence of preterm pre-eclampsia. Results Of the 1611 eligible women, 139 were excluded for UtAPI >90th percentile or if UtAPI was not available. Finally, 804 were included in this post-hoc analysis. Preterm pre-eclampsia occurred in three of 409 (0.7%) women in the aspirin discontinuation group and five of 395 (1.3%) women in the continuation group (−0.53; 95% CI −1.91 to 0.85), indicating non-inferiority of aspirin discontinuation. Conclusions Discontinuing aspirin treatment at 24–28 weeks in women with a UtAPI ≤90th percentile was non-inferior to continuing aspirin treatment until 36 weeks for preventing preterm pre-eclampsia., Instituto de Salud Carlos III (PI17/01944). Roche diagnostics provided the reagents.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia, Post-hoc analysis of StopPRE trial

  • Bonacina, Erika|||0000-0002-8042-8247
  • García Manau, Pablo|||0000-0002-2415-1626
  • López Rodríguez, Mónica
  • Caamiña Álvarez, Sara|||0000-0001-9178-3132
  • Vives, Àngels|||0000-0001-9712-6379
  • Lopez-Quesada, Eva|||0000-0002-4477-3246
  • Ricart, Marta|||0000-0003-0099-6525
  • Maroto, Anna|||0000-0003-3225-9095
  • de Mingo, Laura
  • Pintado, Elena
  • Castillo-Ribelles, Laura|||0000-0001-9380-7839
  • Martin, Lourdes|||0000-0003-1781-5305
  • Rodriguez-Zurita, Alicia|||0000-0003-4177-4726
  • Garcia Cancela, Esperanza|||0000-0001-8924-9096
  • Pallarols, Mar
  • Vidal-Sagnier, Laia
  • Teixidor, Mireia|||0000-0001-8548-1648
  • Orizales Lago, Carmen María|||0000-0001-7184-2799
  • Pérez-Gomez, Adela
  • Ocaña, Vanesa|||0000-0003-2547-5646
  • Puerto Tamayo, Linda Grace|||0000-0001-5539-6397
  • Millán, Pilar
  • Alsius, Mercè
  • Díaz Rodríguez, Sonia|||0000-0001-6689-1895
  • Maiz, Nerea|||0000-0001-8261-6383
  • Carreras Moratonas, Elena|||0000-0003-3471-7248
  • Suy, Anna|||0000-0003-2987-6105
  • Mendoza, Manel|||0000-0002-3030-3833
Objective: To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24-28 weeks. Design: Post-hoc analysis of a clinical trial. Setting: Nine maternity hospitals in Spain. Population or Sample: Pregnant individuals at high risk of pre-eclampsia at 11-13 weeks and normal uterine artery Doppler at 24-28 weeks. Methods: All participants received treatment with daily aspirin at a dose of 150 mg. Participants were randomly assigned, in a 1:1 ratio, either to continue aspirin treatment until 36 weeks (control group) or to discontinue aspirin treatment (intervention group), between September 2019 and September 2021. In this secondary analysis, women with a UtAPI.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial

  • López, Monica
  • Vives, Angels
  • Lopez-Quesada, Eva
  • Castillo-Ribelles, Laura
  • Carreras Moratonas, Elena
  • Bonacina, Erika
  • Garcia-Manau, Pablo
  • Caamiña Álvarez, Sara
  • Maiz, Nerea
  • Suy Franch, Anna
  • Mendoza, Manel
Doppler; Aspirin; Pre-eclampsia, Doppler; Aspirina; Preeclampsia, Doppler; Aspirina; Preeclampsia, Objective To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24–28 weeks. Design Post-hoc analysis of a clinical trial. Setting Nine maternity hospitals in Spain. Population or Sample Pregnant individuals at high risk of pre-eclampsia at 11–13 weeks and normal uterine artery Doppler at 24–28 weeks. Methods All participants received treatment with daily aspirin at a dose of 150 mg. Participants were randomly assigned, in a 1:1 ratio, either to continue aspirin treatment until 36 weeks (control group) or to discontinue aspirin treatment (intervention group), between September 2019 and September 2021. In this secondary analysis, women with a UtAPI >90th percentile at 24–28 weeks were excluded. The non-inferiority margin was set at a difference of 1.9% for the incidence of preterm pre-eclampsia. Main outcome measures Incidence of preterm pre-eclampsia. Results Of the 1611 eligible women, 139 were excluded for UtAPI >90th percentile or if UtAPI was not available. Finally, 804 were included in this post-hoc analysis. Preterm pre-eclampsia occurred in three of 409 (0.7%) women in the aspirin discontinuation group and five of 395 (1.3%) women in the continuation group (−0.53; 95% CI −1.91 to 0.85), indicating non-inferiority of aspirin discontinuation. Conclusions Discontinuing aspirin treatment at 24–28 weeks in women with a UtAPI ≤90th percentile was non-inferior to continuing aspirin treatment until 36 weeks for preventing preterm pre-eclampsia., Instituto de Salud Carlos III (PI17/01944). Roche diagnostics provided the reagents.